Reports
Sale
Global Gynaecology Drugs Market Size, Share, Price, Forecast: By Therapy Type: Hormonal Therapy, Non-Hormonal Therapy; By Indication: Gynaecology Cancers, Endometriosis, Female Infertility, Menopausal Disorder, Other Indication; By Route of Administration; By Distribution Channel; By End User; Regional Analysis; Supplier Landscape; 2024-2032
Global Gynaecology Drugs Market Outlook
The global gynaecology drugs market size was valued at USD 28.54 billion in 2023, driven by the rise in the geriatric population across the globe. The market size is anticipated to grow at a CAGR of 6.1% during the forecast period of 2024-2032 to achieve a value of USD 48.63 billion by 2032.
Gynaecology Drugs: Introduction
The medications that are used by women when they are pregnant are called as gynaecology drugs. The most used gynaecology drugs are analgesics, antimetics, antacids, antimicrobials, antiemetics, antacids, antihistamines, antimicrobials, diuretics, hypnotics, and tranquilizers, among others. These drugs are used to treat certain disorders that occur during pregnancy. The gynaecology drugs are used in the treatment of medical issues with female reproductive system and during pregnancy and childbirth. Hormonal and non-hormonal therapies are the major kind of treatments that are provided in gynaecology drugs. Hormonal therapy is also one of those as it blocks, reduces, or adds hormones that stop the growth of the cancer cells which require the growth of hormones.
Global Gynaecology Drugs Market Analysis
The increasing investments by the key players of the market in the development and research procedures to develop personalized cancer vaccines, including gynaecology cancers, is one of the key factors which is contributing to the gynaecology drugs market growth. Some of them have even reached the trial phases before their final launch in the market. Increased use of genetic sequencing and precision medicine has been going on to develop new drug therapies and cancer treatments to decrease the rate of Gynaecology cancer.
Gynaecology Drugs Market Segmentations
Market Breakup by Therapy Type
- Hormonal Therapy
- Non-Hormonal Therapy
Market Breakup by Indication
- Gynaecology Cancers
- Endometriosis
- Female Infertility
- Menopausal Disorder
- Gynaecology Infections
- Polycystic Ovary Syndrome (PCOS)
- Contraception
- Other Indication
Market by Route of Administration
- Oral
- Parenteral
- Intravaginal
- Others
Market Breakup by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacies
- Others
Market Breakup by End User
- Hospitals
- Specialty Clinics
- Diagnostic Centers
- Research Institute
- Home Healthcare
- Others
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Global Gynaecology drugs Market Overview
The increasing number of women suffering from ovarian cancer is expected to favour the gynaecology drugs market expansion. The gynaecology drug market has been growing and is expected to grow in the coming years as well. Due to the increasing incidence of gynaecology cancer, the market is poised to witness robust growth in the coming years.
Gynaecology Drugs Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Eli Lilly and Company
- Pfizer, Inc.
- Amgen Inc.
- AstraZeneca
- F. Hoffmann-La Roche Ltd.
- Allergan Plc
- Bayer AG Financial Analysis
- AbbVie Inc.
- Lupin Pharmaceuticals Inc.
- Therapeutics MD Inc.
- Ferring Holding S.A.
- Teva Pharmaceutical Industries Limited
- Addex Therapeutics Ltd.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Therapy Type |
|
| Breakup by Indication |
|
| Breakup by Route of Administration |
|
| Breakup by Distribution Channel |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Gynaecology Drugs Market Overview
3.1 Global Gynaecology Drugs Market Historical Value (2017-2023)
3.2 Global Gynaecology Drugs Market Forecast Value (2024-2032)
4 Global Gynaecology Drugs Market Landscape
4.1 Global Gynaecology Drugs Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Gynaecology Drugs Product Landscape
4.2.1 Analysis by Therapy Type
4.2.2 Analysis by Indication
4.2.3 Analysis by Route of Administration
5 Global Gynaecology Drugs Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Gynaecology Drugs Market Segmentation
6.1 Global Gynaecology Drugs Market by Therapy Type
6.1.1 Market Overview
6.1.2 Hormonal Therapy
6.1.3 Non-Hormonal Therapy
6.2 Global Gynaecology Drugs Market by Indication
6.2.1 Market Overview
6.2.2 Gynaecology Cancers
6.2.3 Endometriosis
6.2.4 Female Infertility
6.2.5 Menopausal Disorder
6.2.6 Gynaecology Infections
6.2.7 Polycystic Ovary Syndrome (PCOS)
6.2.8 Contraception
6.2.9 Other Indication
6.3 Global Gynaecology Drugs Market by Route of Administration
6.3.1 Market Overview
6.3.2 Oral
6.3.3 Parenteral
6.3.4 Intravaginal
6.3.5 Others
6.4 Global Gynaecology Drugs Market by Distribution Channel
6.4.1 Market Overview
6.4.2 Hospital Pharmacy
6.4.3 Retail Pharmacy
6.4.4 Online Pharmacies
6.4.5 Others
6.5 Global Gynaecology Drugs Market by End User
6.5.1 Market Overview
6.5.2 Hospitals
6.5.3 Specialty Clinics
6.5.4 Diagnostic Centers
6.5.5 Research Institute
6.5.6 Home Healthcare
6.5.7 Others
6.6 Global Gynaecology Drugs Market by Region
6.6.1 Market Overview
6.6.2 North America
6.6.3 Europe
6.6.4 Asia Pacific
6.6.5 Latin America
6.6.6 Middle East and Africa
7 North America Gynaecology Drugs Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Gynaecology Drugs Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Gynaecology Drugs Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Gynaecology Drugs Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Gynaecology Drugs Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 INDIA CDSCO
16.1.4 JAPAN PMDA
16.1.5 Others
17 Supplier Landscape
17.1 Eli Lilly and Company
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 Pfizer, Inc.
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Amgen Inc.
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 AstraZeneca
17.4.1 Financial Analysis
17.4.2 Financial Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 F. Hoffmann-La Roche Ltd.
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Allergan Plc
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 Bayer AG
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 AbbVie Inc.
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Lupin Pharmaceuticals Inc.
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 Therapeutics MD Inc.
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 Ferring Holding S.A.
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
17.12 Teva Pharmaceutical Industries Limited
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.12.5 Certifications
17.13 Addex Therapeutics Ltd.
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisitions
17.13.5 Certifications
18 Global Gynaecology Drugs Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market for gynaecology drugs attained a value of about USD 28.54 billion in 2023, driven by the rising cases of ovarian cancer.
The gynaecology drugs market size is anticipated to grow at a CAGR of 6.1% during the forecast period of 2024-2032 and reach a market value of USD 48.63 million by 2032.
The rising healthcare sector and theincreasing incidence of ovarian cancer are the key drivers aiding the growth of the market.
The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East and Africa.
The different types of products in the market include hormonal therapy and non-hormonal therapy.
The different indications in gynaecology drugs include gynaecology cancers, endometriosis, female infertility, menopausal disorder, gynaecology infections, polycystic ovary syndrome (PCOS), and contraception, among other indications.
The different routes of administration include oral, parenteral, and intravaginal, among others.
The end users in the market include hospitals, specialty clinics, diagnostic centers, research institute, and home healthcare, among others.
The different types of distribution channels include hospital pharmacy, retail pharmacy, and online pharmacies, among others.
The increasing investments in the development and research procedures to develop personalized cancer vaccines in the market is a major trend in the market.
Key players involved in the market are Pfizer, Inc., Amgen Inc., AstraZeneca, F. Hoffmann-La Roche Ltd., Bayer AG Financial Analysis, AbbVie Inc., Lupin Pharmaceuticals Inc., Therapeutics MD Inc., Ferring Holding S.A., Teva Pharmaceutical Industries Limited, Addex Therapeutics Ltd., Allergan Plc., and Eli Lilly and Company.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER